2.20
+0.005(-0.23%)
Currency In USD
| Previous Close | 2.2 |
| Open | 2.13 |
| Day High | 2.23 |
| Day Low | 2.1 |
| 52-Week High | 7.1 |
| 52-Week Low | 1.26 |
| Volume | 91,595 |
| Average Volume | 176,268 |
| Market Cap | 57.83M |
| PE | -0.75 |
| EPS | -2.93 |
| Moving Average 50 Days | 1.88 |
| Moving Average 200 Days | 2.46 |
| Change | 0.01 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $22.04 as of December 04, 2025 at a share price of $2.2. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $105.26 as of December 04, 2025 at a share price of $2.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
GlobeNewswire Inc.
6 hours ago
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platfo
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire Inc.
Nov 03, 2025 2:05 PM GMT
Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating relapsed/refractory Acute Myeloid Leukemia (AML)Pharmacodynamic
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
GlobeNewswire Inc.
Oct 16, 2025 1:05 PM GMT
Live webcast presentation on Tuesday, October 21st at 11:35 AM ETSOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation